143 related articles for article (PubMed ID: 1906439)
1. Analysis of antitumor effects of OK-432 against syngeneic mouse fibrosarcoma: combination effect of OK-432 and recombinant lymphokines.
Nanjo M; Moriya Y; Hashimoto S; Kataoka M; Saito M; Yoshida T; Ishida N
Int J Immunopharmacol; 1991; 13(2-3):205-15. PubMed ID: 1906439
[TBL] [Abstract][Full Text] [Related]
2. Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed streptococcal preparation.
Saito M; Ichimura O; Kataoka M; Moriya Y; Ueno K; Sugawara Y; Nanjo M; Ishida N
Cancer Immunol Immunother; 1986; 22(3):161-8. PubMed ID: 2425968
[TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor sites in mice.
Saito M; Nanjo M; Kataoka M; Moriya Y; Sugawara Y; Yoshida T; Ishida N
Cancer Res; 1988 Aug; 48(15):4163-7. PubMed ID: 3390809
[TBL] [Abstract][Full Text] [Related]
4. Cytokine-inducing activity and antitumor effect of a liposome-incorporated interferon-gamma-inducing molecule derived from OK-432, a streptococcal preparation.
Okamoto M; Gohda H; Ohe G; Yoshida H; Matsuno T; Saito M; Sato M
J Immunother; 2000 Jan; 23(1):94-103. PubMed ID: 10687142
[TBL] [Abstract][Full Text] [Related]
5. Induction of antitumor L3T4-positive T cells by OK-432 at tumor sites in mice.
Moriya Y; Sato H; Ito K; Saito M; Yoshida T; Ishida N
Cancer Immunol Immunother; 1993; 36(4):245-50. PubMed ID: 8094999
[TBL] [Abstract][Full Text] [Related]
6. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
7. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of mouse natural killer cell activity by combined hyperthermia and streptococcal preparation, OK-432 (Picibanil) treatment.
Taradi M; Urano M; Taradi SK; Maruyama Y
Int J Hyperthermia; 1991; 7(4):653-65. PubMed ID: 1919160
[TBL] [Abstract][Full Text] [Related]
9. [Induction of LAK cells in peritoneal cavity of mice after ip injection of OK-432 and antitumor effect of these LAK cells].
Ishida N; Saito M; Nanjo M
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2681-90. PubMed ID: 6508321
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of anti-cancer immunity by a lipoteichoic-acid-related molecule isolated from a penicillin-killed group A Streptococcus.
Okamoto M; Ohe G; Oshikawa T; Furuichi S; Nishikawa H; Tano T; Ahmed SU; Yoshida H; Moriya Y; Saito M; Sato M
Cancer Immunol Immunother; 2001 Oct; 50(8):408-16. PubMed ID: 11726135
[TBL] [Abstract][Full Text] [Related]
11. [Effect of biological response modifiers on a spontaneous murine renal cell carcinoma regression of metastases caused by the streptococcal preparation OK-432].
Tanji S
Nihon Hinyokika Gakkai Zasshi; 1991 May; 82(5):716-25. PubMed ID: 1875566
[TBL] [Abstract][Full Text] [Related]
12. Combined effects of intraperitoneal administration of recombinant interleukin-2 and streptococcal preparation OK-432 in murine tumors.
Fujioka T; Ishikura K; Tanji S; Okamoto T; Koike H; Aoki H; Ohhori T; Kubo T
Int J Immunopharmacol; 1990; 12(4):419-26. PubMed ID: 2391188
[TBL] [Abstract][Full Text] [Related]
13. Combination chemo-immunotherapy of murine solid tumor with OK-432, G-CSF, IL-2, and chemotherapeutics.
Iida S; Matsuoka S; Kudo C; Moriya Y; Yoshida T; Saito M
Int J Immunopharmacol; 1995 Dec; 17(12):973-80. PubMed ID: 8964656
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of anti-tumor immunity by lipoteichoic acid-related molecule isolated from OK-432, a streptococcal agent, in athymic nude mice bearing human salivary adenocarcinoma: role of natural killer cells.
Okamoto M; Ohe G; Furuichi S; Nishikawa H; Oshikawa T; Tano T; Ahmed SU; Yoshida H; Moriya Y; Matsubara S; Ryoma Y; Saito M; Sato M
Anticancer Res; 2002; 22(6A):3229-39. PubMed ID: 12530069
[TBL] [Abstract][Full Text] [Related]
15. Suppression of alloimmune cytotoxic T lymphocyte (CTL) generation by depletion of NK cells and restoration by interferon and/or interleukin 2.
Suzuki R; Suzuki S; Ebina N; Kumagai K
J Immunol; 1985 Apr; 134(4):2139-48. PubMed ID: 2579129
[TBL] [Abstract][Full Text] [Related]
16. [Combined effect of intraperitoneally administered OK-432 and recombinant interleukin (rIL-2) against mouse tumors].
Fujioka T; Shiraishi M; Tanji S; Koike H; Kumagai K; Kubo T; Ohhori T
Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):948-56. PubMed ID: 2789265
[TBL] [Abstract][Full Text] [Related]
17. Effective in vivo induction of lymphokine-activated killer (LAK) cells by pretreatment with a streptococcal preparation, OK-432.
Shimoda K; Saito T; Kobayashi M; Nomoto K
Biotherapy; 1992; 5(1):63-9. PubMed ID: 1389903
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells.
Ujiie T
Jpn J Exp Med; 1988 Apr; 58(2):109-14. PubMed ID: 3261814
[TBL] [Abstract][Full Text] [Related]
19. Induction of natural killer (NK) activity in mice by injection of chromomycin A3.
Kambe M; Kanamaru R; Mitachi Y; Wakui A
Tohoku J Exp Med; 1991 Apr; 163(4):279-88. PubMed ID: 1909057
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4.
Ahmed SU; Okamoto M; Oshikawa T; Tano T; Sasai A; Kan S; Hiroshima T; Ohue H; Moriya Y; Ryoma Y; Saito M; Sato M
J Immunother; 2004; 27(6):432-41. PubMed ID: 15534487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
